Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 105

1.

Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA).

Danaher P, Warren S, Lu R, Samayoa J, Sullivan A, Pekker I, Wallden B, Marincola FM, Cesano A.

J Immunother Cancer. 2018 Jun 22;6(1):63. doi: 10.1186/s40425-018-0367-1.

2.

Immune oncology, immune responsiveness and the theory of everything.

Turan T, Kannan D, Patel M, Matthew Barnes J, Tanlimco SG, Lu R, Halliwill K, Kongpachith S, Kline DE, Hendrickx W, Cesano A, Butterfield LH, Kaufman HL, Hudson TJ, Bedognetti D, Marincola F, Samayoa J.

J Immunother Cancer. 2018 Jun 5;6(1):50. doi: 10.1186/s40425-018-0355-5.

3.

Bringing the next Generation of Immuno-Oncology Biomarkers to the Clinic.

Cesano A, Warren S.

Biomedicines. 2018 Feb 2;6(1). pii: E14. doi: 10.3390/biomedicines6010014. Review.

4.

The need for a network to establish and validate predictive biomarkers in cancer immunotherapy.

Masucci GV, Cesano A, Eggermont A, Fox BA, Wang E, Marincola FM, Ciliberto G, Dobbin K, Puzanov I, Taube J, Wargo J, Butterfield LH, Villabona L, Thurin M, Postow MA, Sondel PM, Demaria S, Agarwala S, Ascierto PA.

J Transl Med. 2017 Nov 3;15(1):223. doi: 10.1186/s12967-017-1325-2.

5.

Immunotherapy biomarkers 2016: overcoming the barriers.

Gulley JL, Berzofsky JA, Butler MO, Cesano A, Fox BA, Gnjatic S, Janetzki S, Kalavar S, Karanikas V, Khleif SN, Kirsch I, Lee PP, Maccalli C, Maecker H, Schlom J, Seliger B, Siebert J, Stroncek DF, Thurin M, Yuan J, Butterfield LH.

J Immunother Cancer. 2017 Mar 21;5(1):29. doi: 10.1186/s40425-017-0225-6.

6.

Integration of B-cell receptor-induced ERK1/2 phosphorylation and mutations of SF3B1 gene refines prognosis in treatment-naïve chronic lymphocytic leukemia.

Cavallini C, Visco C, Putta S, Rossi D, Mimiola E, Purvis N, Lovato O, Perbellini O, Falisi E, Facco M, Trentin L, Romanelli MG, Semenzato G, Ambrosetti A, Gaidano G, Pizzolo G, Cesano A, Scupoli MT.

Haematologica. 2017 Apr;102(4):e144-e147. doi: 10.3324/haematol.2016.154450. Epub 2016 Dec 7. No abstract available.

7.

Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation.

Masucci GV, Cesano A, Hawtin R, Janetzki S, Zhang J, Kirsch I, Dobbin KK, Alvarez J, Robbins PB, Selvan SR, Streicher HZ, Butterfield LH, Thurin M.

J Immunother Cancer. 2016 Nov 15;4:76. eCollection 2016. Review.

8.

Validation of biomarkers to predict response to immunotherapy in cancer: Volume II - clinical validation and regulatory considerations.

Dobbin KK, Cesano A, Alvarez J, Hawtin R, Janetzki S, Kirsch I, Masucci GV, Robbins PB, Selvan SR, Streicher HZ, Zhang J, Butterfield LH, Thurin M.

J Immunother Cancer. 2016 Nov 15;4:77. doi: 10.1186/s40425-016-0179-0. eCollection 2016. Review.

9.

Placental immune editing switch (PIES): learning about immunomodulatory pathways from a unique case report.

Bronchud MH, Tresserra F, Xu W, Warren S, Cusido M, Zantop B, Zenclussen AC, Cesano A.

Oncotarget. 2016 Dec 13;7(50):83817-83827. doi: 10.18632/oncotarget.13306.

10.

Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.

Ascierto PA, Agarwala S, Botti G, Cesano A, Ciliberto G, Davies MA, Demaria S, Dummer R, Eggermont AM, Ferrone S, Fu YX, Gajewski TF, Garbe C, Huber V, Khleif S, Krauthammer M, Lo RS, Masucci G, Palmieri G, Postow M, Puzanov I, Silk A, Spranger S, Stroncek DF, Tarhini A, Taube JM, Testori A, Wang E, Wargo JA, Yee C, Zarour H, Zitvogel L, Fox BA, Mozzillo N, Marincola FM, Thurin M.

J Transl Med. 2016 Nov 15;14(1):313.

11.

nCounter(®) PanCancer Immune Profiling Panel (NanoString Technologies, Inc., Seattle, WA).

Cesano A.

J Immunother Cancer. 2015 Dec 15;3:42. doi: 10.1186/s40425-015-0088-7. eCollection 2015. No abstract available.

12.

Immune monitoring technology primer: Single Cell Network Profiling (SCNP).

Hawtin RE, Cesano A.

J Immunother Cancer. 2015 Aug 18;3:34. doi: 10.1186/s40425-015-0075-z. eCollection 2015. No abstract available.

13.

Cell signaling-based classifier predicts response to induction therapy in elderly patients with acute myeloid leukemia.

Cesano A, Willman CL, Kopecky KJ, Gayko U, Putta S, Louie B, Westfall M, Purvis N, Spellmeyer DC, Marimpietri C, Cohen AC, Hackett J, Shi J, Walker MG, Sun Z, Paietta E, Tallman MS, Cripe LD, Atwater S, Appelbaum FR, Radich JP.

PLoS One. 2015 Apr 17;10(4):e0118485. doi: 10.1371/journal.pone.0118485. eCollection 2015.

14.

Quantitative measurement of alterations in DNA damage repair (DDR) pathways using single cell network profiling (SCNP).

Rosen DB, Leung LY, Louie B, Cordeiro JA, Conroy A, Shapira I, Fields SZ, Cesano A, Hawtin RE.

J Transl Med. 2014 Jun 25;12:184. doi: 10.1186/1479-5876-12-184.

15.

High-dimensional analysis of the aging immune system: verification of age-associated differences in immune signaling responses in healthy donors.

Longo DM, Louie B, Ptacek J, Friedland G, Evensen E, Putta S, Atallah M, Spellmeyer D, Wang E, Pos Z, Marincola FM, Schaeffer A, Lukac S, Railkar R, Beals CR, Cesano A, Carayannopoulos LN, Hawtin RE.

J Transl Med. 2014 Jun 21;12:178. doi: 10.1186/1479-5876-12-178.

16.

Immune system functional pathway analysis using single cell network profiling (SCNP): a novel tool in cancer immunotherapy.

Cesano A, Spellmeyer D.

Methods Mol Biol. 2014;1102:583-99. doi: 10.1007/978-1-62703-727-3_31.

PMID:
24259000
17.

Age-related changes of healthy bone marrow cell signaling in response to growth factors provide insight into low risk MDS.

Kornblau SM, Cohen AC, Soper D, Huang YW, Cesano A.

Cytometry B Clin Cytom. 2014 Nov;86(6):383-96. doi: 10.1002/cyto.b.21125. Epub 2013 Sep 16.

18.

Age-related changes of healthy bone marrow cell signaling in response to growth factors provide insight into low risk MDS.

Kornblau SM, Cohen AC, Soper D, Huang YW, Cesano A.

Cytometry B Clin Cytom. 2013 Aug 20. doi: 10.1002/cytob.21125. [Epub ahead of print]

19.

Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012".

Ascierto PA, Grimaldi AM, Acquavella N, Borgognoni L, Calabrò L, Cascinelli N, Cesano A, Del Vecchio M, Eggermont AM, Faries M, Ferrone S, Fox BA, Gajewski TF, Galon J, Gnjatic S, Gogas H, Kashani-Sabet M, Kaufman HL, Larkin J, Lo RS, Mantovani A, Margolin K, Melief C, McArthur G, Palmieri G, Puzanov I, Ribas A, Seliger B, Sosman J, Suenaert P, Tarhini AA, Trinchieri G, Vidal-Vanaclocha F, Wang E, Ciliberto G, Mozzillo N, Marincola FM, Thurin M.

J Transl Med. 2013 Jun 3;11:137. doi: 10.1186/1479-5876-11-137.

20.

Development and validation of a single-cell network profiling assay-based classifier to predict response to induction therapy in paediatric patients with de novo acute myeloid leukaemia: a report from the Children's Oncology Group.

Lacayo NJ, Alonzo TA, Gayko U, Rosen DB, Westfall M, Purvis N, Putta S, Louie B, Hackett J, Cohen AC, Cesano A, Gerbing R, Ravindranath Y, Dahl GV, Gamis A, Meshinchi S.

Br J Haematol. 2013 Jul;162(2):250-62. doi: 10.1111/bjh.12370. Epub 2013 May 20.

21.

Functional pathway analysis using SCNP of FLT3 receptor pathway deregulation in AML provides prognostic information independent from mutational status.

Cesano A, Putta S, Rosen DB, Cohen AC, Gayko U, Mathi K, Woronicz J, Hawtin RE, Cripe L, Sun Z, Tallman MS, Paietta E.

PLoS One. 2013;8(2):e56714. doi: 10.1371/journal.pone.0056714. Epub 2013 Feb 19.

22.

AKT signaling as a novel factor associated with in vitro resistance of human AML to gemtuzumab ozogamicin.

Rosen DB, Harrington KH, Cordeiro JA, Leung LY, Putta S, Lacayo N, Laszlo GS, Gudgeon CJ, Hogge DE, Hawtin RE, Cesano A, Walter RB.

PLoS One. 2013;8(1):e53518. doi: 10.1371/journal.pone.0053518. Epub 2013 Jan 8.

23.

Single cell network profiling assay in bladder cancer.

Covey TM, Vira MA, Westfall M, Gulrajani M, Cholankeril M, Okhunov Z, Levey HR, Marimpietri C, Hawtin R, Fields SZ, Cesano A.

Cytometry A. 2013 Apr;83(4):386-95. doi: 10.1002/cyto.a.22244. Epub 2013 Jan 8.

24.

Association between B-cell receptor responsiveness and disease progression in B-cell chronic lymphocytic leukemia: results from single cell network profiling studies.

Cesano A, Perbellini O, Evensen E, Chu CC, Cioffi F, Ptacek J, Damle RN, Chignola R, Cordeiro J, Yan XJ, Hawtin RE, Nichele I, Ware JR, Cavallini C, Lovato O, Zanotti R, Rai KR, Chiorazzi N, Pizzolo G, Scupoli MT.

Haematologica. 2013 Apr;98(4):626-34. doi: 10.3324/haematol.2012.071910. Epub 2012 Nov 9.

25.

Applications of multiparametric flow cytometry: providing new insights into biology to bridge the gap between research discovery and clinical application.

Cesano A, Parkinson D.

Cytometry A. 2012 Sep;81(9):732-3. doi: 10.1002/cyto.a.22087. Epub 2012 Jun 21. No abstract available.

26.

Racial differences in B cell receptor signaling pathway activation.

Longo DM, Louie B, Mathi K, Pos Z, Wang E, Hawtin RE, Marincola FM, Cesano A.

J Transl Med. 2012 Jun 6;10:113. doi: 10.1186/1479-5876-10-113.

27.

Assessing signaling pathways associated with in vitro resistance to cytotoxic agents in AML.

Rosen DB, Cordeiro JA, Cohen A, Lacayo N, Hogge D, Hawtin RE, Cesano A.

Leuk Res. 2012 Jul;36(7):900-4. doi: 10.1016/j.leukres.2012.02.022. Epub 2012 Apr 21.

PMID:
22521550
28.

Functional pathway analysis in acute myeloid leukemia using single cell network profiling assay: effect of specimen source (bone marrow or peripheral blood) on assay readouts.

Cesano A, Rosen DB, O'Meara P, Putta S, Gayko U, Spellmeyer DC, Cripe LD, Sun Z, Uno H, Litzow MR, Tallman MS, Paietta E.

Cytometry B Clin Cytom. 2012 May;82(3):158-72. doi: 10.1002/cyto.b.21007. Epub 2012 Feb 14.

29.

Single-cell network profiling of peripheral blood mononuclear cells from healthy donors reveals age- and race-associated differences in immune signaling pathway activation.

Longo DM, Louie B, Putta S, Evensen E, Ptacek J, Cordeiro J, Wang E, Pos Z, Hawtin RE, Marincola FM, Cesano A.

J Immunol. 2012 Feb 15;188(4):1717-25. doi: 10.4049/jimmunol.1102514. Epub 2012 Jan 13.

30.

Inter-donor variation in cell subset specific immune signaling responses in healthy individuals.

Longo DM, Louie B, Wang E, Pos Z, Marincola FM, Hawtin RE, Cesano A.

Am J Clin Exp Immunol. 2012 Apr 24;1(1):1-11. Print 2012.

31.

Association of reactive oxygen species-mediated signal transduction with in vitro apoptosis sensitivity in chronic lymphocytic leukemia B cells.

Palazzo AL, Evensen E, Huang YW, Cesano A, Nolan GP, Fantl WJ.

PLoS One. 2011;6(10):e24592. doi: 10.1371/journal.pone.0024592. Epub 2011 Oct 10.

32.

Poly(ADP-ribose) polymerase-1 inhibition: preclinical and clinical development of synthetic lethality.

Leung M, Rosen D, Fields S, Cesano A, Budman DR.

Mol Med. 2011;17(7-8):854-62. doi: 10.2119/molmed.2010.00240. Epub 2011 Mar 11. Review.

33.

Signaling changes in the stem cell factor-AKT-S6 pathway in diagnostic AML samples are associated with disease relapse.

Kornblau SM, Covey T, Putta S, Cohen A, Woronicz J, Fantl WJ, Gayko U, Cesano A.

Blood Cancer J. 2011 Feb;1(2):e3. doi: 10.1038/bcj.2010.2. Epub 2011 Feb 11. No abstract available.

34.

Modulated multiparametric phosphoflow cytometry in hematological malignancies: technology and clinical applications.

Covey TM, Cesano A.

Best Pract Res Clin Haematol. 2010 Sep;23(3):319-31. doi: 10.1016/j.beha.2010.07.002. Epub 2010 Nov 10. Review.

PMID:
21112033
35.

Functional characterization of FLT3 receptor signaling deregulation in acute myeloid leukemia by single cell network profiling (SCNP).

Rosen DB, Minden MD, Kornblau SM, Cohen A, Gayko U, Putta S, Woronicz J, Evensen E, Fantl WJ, Cesano A.

PLoS One. 2010 Oct 27;5(10):e13543. doi: 10.1371/journal.pone.0013543.

36.

Distinct patterns of DNA damage response and apoptosis correlate with Jak/Stat and PI3kinase response profiles in human acute myelogenous leukemia.

Rosen DB, Putta S, Covey T, Huang YW, Nolan GP, Cesano A, Minden MD, Fantl WJ.

PLoS One. 2010 Aug 25;5(8):e12405. doi: 10.1371/journal.pone.0012405.

37.

Dynamic single-cell network profiles in acute myelogenous leukemia are associated with patient response to standard induction therapy.

Kornblau SM, Minden MD, Rosen DB, Putta S, Cohen A, Covey T, Spellmeyer DC, Fantl WJ, Gayko U, Cesano A.

Clin Cancer Res. 2010 Jul 15;16(14):3721-33. doi: 10.1158/1078-0432.CCR-10-0093. Epub 2010 Jun 4.

38.

Single-cell network profiling (SCNP) by flow cytometry in autoimmune disease.

Covey TM, Cesano A, Parkinson DR.

Autoimmunity. 2010 Nov;43(7):550-9. doi: 10.3109/08916931003674774. Review.

PMID:
20482423
39.

Single cell network profiling (SCNP): mapping drug and target interactions.

Covey TM, Putta S, Cesano A.

Assay Drug Dev Technol. 2010 Jun;8(3):321-43. doi: 10.1089/adt.2009.0251.

PMID:
20158439
40.

Insights into acute myeloid leukemia via single cell network profiling.

Kornblau SM, Minden MD, Hogge D, Cohen A, Cesano A.

Clin Lab Int. 2010 Feb-Mar;34(1):12-15.

41.

Patient-specific classifications of human malignant disease.

Parkinson DR, Cesano A.

Curr Opin Mol Ther. 2009 Jun;11(3):252-9. Review.

PMID:
19479658
42.

Role of palifermin in fluorouracil-based therapy for metastatic colorectal cancer.

Zalcberg JR, Rosen LS, Abdi E, Davis ID, Gutheil J, Schnell FM, Cesano A, Gayko U, Chen MG, Clarke S.

J Clin Oncol. 2008 Mar 10;26(8):1386-7. doi: 10.1200/JCO.2007.15.4492. No abstract available.

PMID:
18323563
43.

Pharmacokinetics of palifermin administered as the standard dose and as a collapsed dose in patients with hematologic malignancies.

Zia-Amirhosseini P, Hurd DD, Salfi M, Cheah TC, Aycock J, Cesano A.

Pharmacotherapy. 2007 Oct;27(10):1353-60.

PMID:
17896890
44.

Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy.

Rosen LS, Abdi E, Davis ID, Gutheil J, Schnell FM, Zalcberg J, Cesano A, Gayko U, Chen MG, Clarke S.

J Clin Oncol. 2006 Nov 20;24(33):5194-200. Epub 2006 Oct 30.

PMID:
17075109
45.

Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab.

Carnahan J, Stein R, Qu Z, Hess K, Cesano A, Hansen HJ, Goldenberg DM.

Mol Immunol. 2007 Feb;44(6):1331-41. Epub 2006 Jun 30.

PMID:
16814387
46.

Pharmacokinetics, pharmacodynamics, and safety assessment of palifermin (rHuKGF) in healthy volunteers.

Zia-Amirhosseini P, Salfi M, Leese P, Yates W, Danilenko DM, Ring B, Cesano A, Sullivan JT.

Clin Pharmacol Ther. 2006 Jun;79(6):558-69.

PMID:
16765144
47.

Palifermin reduces patient-reported mouth and throat soreness and improves patient functioning in the hematopoietic stem-cell transplantation setting.

Stiff PJ, Emmanouilides C, Bensinger WI, Gentile T, Blazar B, Shea TC, Lu J, Isitt J, Cesano A, Spielberger R.

J Clin Oncol. 2006 Nov 20;24(33):5186-93. Epub 2006 Jan 3.

PMID:
16391299
48.

Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results.

Leonard JP, Coleman M, Ketas JC, Chadburn A, Furman R, Schuster MW, Feldman EJ, Ashe M, Schuster SJ, Wegener WA, Hansen HJ, Ziccardi H, Eschenberg M, Gayko U, Fields SZ, Cesano A, Goldenberg DM.

Clin Cancer Res. 2004 Aug 15;10(16):5327-34.

49.

Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties.

Carnahan J, Wang P, Kendall R, Chen C, Hu S, Boone T, Juan T, Talvenheimo J, Montestruque S, Sun J, Elliott G, Thomas J, Ferbas J, Kern B, Briddell R, Leonard JP, Cesano A.

Clin Cancer Res. 2003 Sep 1;9(10 Pt 2):3982S-90S.

50.

CD22-directed monoclonal antibody therapy for lymphoma.

Siegel AB, Goldenberg DM, Cesano A, Coleman M, Leonard JP.

Semin Oncol. 2003 Aug;30(4):457-64. Review.

PMID:
12939714

Supplemental Content

Loading ...
Support Center